LONDON, UNITED KINGDOM — September 30, 2025 — Leads & Copy — Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) has released its half-year results for the six-month period ending June 30, 2025. The company is advancing its mission to extend healthspan through proprietary SIRT6 centenarian-based gene therapies in both human and animal health programs.
Genflow’s human health pipeline targets MASH, sarcopenia, Werner Syndrome, and ophthalmology. The company has repositioned GF-1002 to target advanced MASH with fibrosis, addressing a significant unmet need. In ophthalmology, SIRT6-based therapies show promise in corneal pathologies and glaucoma, potentially shifting treatment from symptom management to neuroprotection.
The animal health pipeline includes a clinical trial in dogs with partner Syngene, testing GF-1004 for sarcopenia and healthspan. Early studies confirm the safety of GF-1004, with initial efficacy data expected within five months. Genflow is also in discussions with animal health companies regarding age-related decline in companion animals.
As of June 30, 2025, the Group had cash reserves of £279,445, derived from equity fundraising of £868,698 during H1 2025. Administration expenses totaled £982,725, including research and development costs of £665,862.
Looking ahead, 2026 is expected to be a pivotal year, with progress in MASH, ophthalmology, and the canine trial. The company is also working to secure non-dilutive funding, with support from the Wallonia Region to advance GF-1002.
Tamara Joseph, Chairman, thanked shareholders, partners, and the team for their support in translating SIRT6 science into therapies.
Contacts:
Dr Eric Leire, CEO, Genflow Biosciences, +32-477-495-881
Jonathan Paterson, Investor Relations, Harbor Access, +1 475 477 9401, Jonathan.Paterson@Harbor-access.com
Jon Critchley, Capital Plus Partners Ltd, +44 207 432 0501
Source: Genflow Biosciences Plc
